Delving into the Latest Updates on ZP5-9676 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ZP5-9676

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Helminthiasis

Inactive Indication-

Originator Organization

Zero Point Five Therapeutics, Inc.

Active Organization

Zero Point Five Therapeutics, Inc.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants

This is a Phase 3, multi-center, prospective, randomized, double-blind, placebo-controlled study to evaluate the effectiveness, safety, and tolerability of ZP5-9676 compared to placebo for the treatment of STH infections. Approximately 300 participants will be enrolled, randomized at the Baseline visit (Day 1) to one of the following treatments in a 1:1 ratio of active and placebo.

Start Date01 Oct 2024

Sponsor / Collaborator

Zero Point Five Therapeutics, Inc.

PACTR202404505131714

/ SuspendedPhase 3

A Phase 3, multi-center, prospective, randomized, double-blind, placebo- controlled study to evaluate the effectiveness and safety of ZP5-9676 for the treatment of Hookworm (Ancylostoma duodenale and Necator americanus), Ascaris lumbricoides, and Trichuris trichiura in pediatric and adult Participants

Start Date17 Jun 2024

Sponsor / Collaborator

Zero Point Five Therapeutics, Inc.

100 Clinical Results associated with ZP5-9676

Login to view more data

100 Translational Medicine associated with ZP5-9676

Login to view more data

100 Patents (Medical) associated with ZP5-9676

Login to view more data

100 Deals associated with ZP5-9676

Login to view more data